Table 3.

Multivariate Cox regression model for progression-free survival (PFS) for all patients receiving first-line molecular targeted therapy (MTT).

Prognostic factor for PFS	HR	95% CI	P value
MTT agent
Everolimus	1
Sunitinib	3.47	1.46–8.25	0.005
Age at baseline	0.99	0.96–1.01	0.285
Site of primary
Pancreas	1
Small intestine	0.71	0.28–1.76	0.453
Lung/thymus	1.16	0.27–5.03	0.842
Unknown primary (UPO)	1.81	0.31–10.63	0.511
Liver tumour load
No liver metastases	1		0.75
<5 unilobar liver metastases	1.98	0.31–12.55	0.467
5–10 unilobar and/or bilobar liver metastases	0.95	0.15–6.15	0.954
>10 liver metastases or diffuse liver metastases	1.51	0.32–7.13	0.603
KI67 groups
KI67 <3%	1
KI67 3–20%	0.751	0.32–1.79	0.516
KI67 >20%	6.38	1.30–31.25	0.022
SRS or 68Ga-PET
Negative	1		0.209
Positive	0.99	0.35–2.86	0.996
Unknown	0.31	0.06–1.57	0.158
Prior resective surgery
No	1
Yes	0.7	0.35–1.37	0.295
Prior chemotherapy
No	1
Yes	2.71	1.17–6.3	0.021

Bold indicates statistical significance.

CI, confidence interval; Ga, Gallium; HR, hazard ratio; MEN1, multiple endocrine neoplasia type 1; MTT, molecular targeted therapy; SRS, somatostatin receptor scintigraphy.